Enzalutamide in Non-Metastatic — vs Metastatic Prostate Cancer

Enzalutamide is used in the non-metastatic setting when PSA is rising rapidly on standard hormone therapy, even though no spread has been detected on scans yet. The reason it is prescribed at this point is that a fast-rising PSA in this situation is a sign that spread is likely to follow. The drug is intended to delay that. The word 'advanced' gets applied loosely in news coverage and online forums — the more useful question is which setting your cancer is in and what the treatment is aiming for. Ask your oncologist to explain the specific reason it was chosen for you.

In most situations, no. Enzalutamide is added to ongoing androgen deprivation therapy rather than replacing it, across most of the settings where it is prescribed. Confirm this with your own team, because the combination depends on your individual case. If you are uncertain whether to continue your injections or implants now that you are taking tablets, ask before making any change — stopping ADT without guidance could affect how well the treatment works.

Your PSA is the main marker your team will follow. A falling PSA after starting treatment suggests the drug is having an effect. In the non-metastatic setting, repeat imaging will check whether the cancer has remained stable. In the metastatic setting, scans assess whether existing disease is responding or progressing. Your oncologist will tell you what to look for and over what timeframe — the expected pattern differs between settings, so there is no single answer that applies to everyone.

Dizziness is a recognised side effect, and a small number of people on enzalutamide experience seizures — rare, but relevant to driving. Your team will ask about your seizure history before prescribing. In the first few weeks, pay attention to how the drug affects you before resuming long drives or complex road conditions. If you notice dizziness, confusion, or anything neurological, tell your team before driving again. If your work involves driving, discuss this specifically with your treating team.

Enzalutamide is typically continued for as long as it is working and you are tolerating it. In the non-metastatic setting, treatment continues until there is evidence of spread or until the cancer stops responding. In the metastatic settings, it is continued until the disease progresses. The duration varies considerably between patients. Ask your oncologist what signs they will look for when deciding whether to continue, adjust, or change treatment — that gives you a clearer picture than a time estimate.

Yes, and this matters for safety. Enzalutamide interacts with a number of commonly used medicines, including some used for heart conditions, blood thinning, seizures, and cholesterol. It can reduce the effectiveness of other drugs by speeding up how the body processes them — this includes some medicines available without a prescription. Tell your oncology team and your regular doctor about every medicine, supplement, and herbal remedy you are taking before you start, and whenever you add anything new. Do not stop or change any medicine without checking with your team first.